Bavarian Nordic (BAVA CO) stock market data APIs
kr188.3525
2.8(1.5%)
as of December 8, 2025
Try our APIs with
free plan!
Bavarian Nordic Financial Data Overview
Price chart is built with
Anychart
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Prev. Close
188.3525
Open
191.1479
High
192.5282
Low
188.0204
52 wk Range
123.3-244.8
Market Cap
18 516 M
P/E Ratio
10.3887
Shares Outstanding
78 240 K
Revenue
6 455 M
Beta
1.096
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Bavarian Nordic (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bavarian Nordic data using free add-ons & libraries
Get Bavarian Nordic Fundamental Data
Bavarian Nordic Fundamental data includes:
- Net Revenue: 6 455 M
- EBITDA: 2 148 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-14
- EPS/Forecast: 1.9
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bavarian Nordic News
New
Bavarian Nordic to Launch Share Buy-back Program of up to DKK 500 Million
Bavarian Nordic A/S COPENHAGEN, Denmark, December 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced its intent to launch a one-time share buy-back program of up to DKK 500 million to be exe...
Should You Reassess Bavarian Nordic After Vaccine Pipeline and Share Price Drop?
If you have ever wondered whether Bavarian Nordic is trading at a bargain or slipping past fair value, you are not alone. Let's dig in together and see what's really going on with this stock. While Ba...
Bavarian Nordic to Host a Shareholder Information Meeting on December 11, 2025 in Copenhagen
Bavarian Nordic A/S COPENHAGEN, Denmark, November 26, 2025 – Bavarian Nordic A/S invites its shareholders for a meeting and dialogue with the company’s board and management, who will provide the ...
Bavarian Nordic AS (BVNKF) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...
This article first appeared on GuruFocus. Release Date: November 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Bavar...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
